


## Transforming Cancer Therapy Through Precision Immuno-Oncology


### Company Overview

PDX Pharmaceuticals is a preclinical-stage biotechnology company developing innovative immunotherapies to overcome resistance to current cancer treatments. Founded by an expert in drug delivery and immune modulation, PDX Pharma focuses on precision-engineered nanomedicines and vaccines that enable effective and durable cancer immunotherapy—especially in “cold” tumors that do not respond to current immune checkpoint inhibitors.


### Technology Platform: PDX-NP™



### Pipeline Highlights



### Superior Efficacy to Standard of Care



### Market Opportunity

- Global immuno-oncology market: \$100B+ by 2030
- Unmet need in immune checkpoint blockade-resistant cancers
- Personalized cancer vaccines projected to reach \$5B+ by 2028

### Why PDX Pharma

- Robust IPs: 7 issued patents and 35+ pending patents across delivery, formulation, and immunotherapy
- Strong Preclinical Data: Published in 10+ high impact journals, and funded by \$10M+ grants from the National Cancer Institute (NCI) and \$3.5M seed investment
- Strategic Collaborations: With leading academic institutions (OHSU and KCI)
- Experienced Team: Scientific founder and leadership team with deep expertise in translational research, regulatory strategy, and biotech entrepreneurship

**Investment Opportunity:** PDX Pharma is seeking strategic partners and investors to:

- Accelerate GMP manufacturing, GLP toxicology, and advance ARAC-02 toward clinical trials by 2026 and expand other pipelines toward clinical applications
- Potential matching fund of \$7.5M from the NCI and state funds.

**Contact:** Dr. Wassana Yantasee, CEO, [yantasee@pdxpharm.com](mailto:yantasee@pdxpharm.com);

Dr. Worapol Ngamcherdtrakul, COO, [worapol@pdxpharm.com](mailto:worapol@pdxpharm.com); Website: [www.pdxpharm.com](http://www.pdxpharm.com)